Dr. Medford is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-643-0596Fax+1 617-643-6443
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 2017 - 2019
Johns Hopkins University School of MedicineClass of 2015
Certifications & Licensure
MA State Medical License 2016 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 138 citationsESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patientsDavid Chu, Costanza Paoletti, Christina L. Gersch, Dustin A. VanDenBerg, Daniel J. Zabransky
Clinical Cancer Research. 2016-02-15 - 41 citationsHotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivationW. Brian Dalton, Eric Helmenstine, Noel Walsh, Lukasz P. Gondek, Dhanashree S. Kelkar
The Journal of Clinical Investigation. 2019-11-01 - 69 citationsKi-67 is required for maintenance of cancer stem cells but not cell proliferationJustin Cidado, Hong Yuen Wong, D. Marc Rosen, Ashley Cimino-Mathews, Joseph P. Garay
Oncotarget. 2016-01-28
Press Mentions
Identifying Opportunities to De-Escalate Adjuvant Therapy in Localized HER2+ Breast CancerMay 23rd, 2023- Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022November 26th, 2022
CDK 4/6 Inhibitor, Ribociclib, with Adjuvant Endocrine Therapy for ER-Positive Breast Cancer (LEADER)April 2nd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
